This site is intended for US healthcare professionals

Hero background shape image Hero background shape image

Purposefully designed,
trusted delivery

Collage layering paper shapes Collage layering paper shapes
  • yellow plus sign

    Administration support

    Need injection training and resources for your team?

    Support includes:

    • ZOLADEX introduction and administration overview
    • Interactive in-service using ZOLADEX demonstration kits
    • Printed reference materials including ZOLADEX Administration Guide
    • Access to ZOLADEX Administration Video
    • Dedicated contact for future follow-up training or questions
    Request training
  • yellow plus sign

    Nurse
    On-Demand program

    Urgent ZOLADEX dosing, administration, and usage questions?

    The TerSera Nurse On-Demand program offers real-time, peer-to-peer clinical education.

    Call 1-877-99-NURSE (68773)

    Monday–Friday, 8 AM to 5:30 PM ET
    Messages left after hours will be returned the next business day.

ZOLADEX is the only ready-to-use, subcutaneous, biodegradable GnRH agonist implant – no assembly, mixing, or refrigeration required1,2

The ZOLADEX SafeSystem® Syringe:

  • Biodegradable implant delivered through a triple-beveled, siliconized needle
  • Designed with a protective needle sleeve to reduce needlestick injuries by automatically covering the needle upon withdrawal3

Each syringe is provided with a convenience pack
(contains gauze, alcohol wipe, and bandage)

ZOLADEX 3.6 mg SafeSystem Syringe, Convenience pack, and ZOLADEX 10.8 mg SafeSystem Syringe

1.5+ million doses administered in breast cancer4*

*From TerSera launch of ZOLADEX in January 2017 through March 2026.

In a study with nurses, it took an average of 1.70 minutes to prepare and deliver ZOLADEX 3.6 mg5†

Circle with 91% in the center

agreed that it was
easy to prepare ZOLADEX prior to administration

Circle with 85% in the center

agreed that there were
good safety precautions
with ZOLADEX

Circle with 76% in the center

agreed that the
ZOLADEX syringe was
easy to manipulate

Circle with 67% in the center

felt confident
about using the ZOLADEX syringe

Study design: Randomized crossover study with 82 nurses timed in the simulated administration (preparation and delivery) of the system used to administer ZOLADEX and the system used to administer another GnRH agonist.‡ Preferences and perceptions of the ease of use and relative safety of the two injection systems were also assessed via questionnaire.

†Range: 0.5—3.05 min.

‡Study conducted in the UK; GnRH agonist used for comparison was product marketed only in the UK.

In a study with patients, the majority reported minimal pain (VAS <10 mm) from the ZOLADEX 3.6 mg injection6§

Visual Analogue Scale with needle pointing between 0 and 10

There was no significant difference between the pain levels experienced from injections of ZOLADEX compared to another subcutaneous GnRH agonist.

Study design: A total of 50 prostate cancer patients were blindfolded and administered either ZOLADEX or another GnRH agonist into the anterior abdominal wall.6¶ Each group (24 ZOLADEX and 26 other GnRH agonist) received 2 injections 4 weeks apart. Following each injection, patients were asked to record the pain of injection on a visual analogue scale ranging from 0 mm (no discomfort) to 100 mm (maximal discomfort).

§Injection 1: Median range 5 (0-38) mm; Injection 2: Median range 7 (0-51) mm.

Study conducted in the UK; GnRH agonist used for comparison was product marketed only in the UK.

Watch this helpful video for more information on how to administer ZOLADEX

ZOLADEX administration technique

Follow the steps below and download this helpful guide for your office.

1. Prepare the patient:

Put the patient in a comfortable position with the upper part of the body slightly raised. Prepare an area of the anterior abdominal wall below and two inches out from the navel line with an alcohol swab.7

NOTE: Caution should be taken when injecting ZOLADEX into the anterior abdominal wall due to the proximity of underlying inferior epigastric artery and its branches.

Bare anterior abdominal wall indicating area for ZOLADEX (goserelin implant) subcutaneous injection

2. Prepare the injection:

Examine the foil pouch for damage, then open. Empty pouch onto a clean surface rather than pulling the syringe out of the pouch as it is possible to inadvertently pull the plunger off of the syringe.

Examine the syringe for damage, then hold the syringe at a slight angle to the light and confirm at least part of the ZOLADEX implant is visible. There is no need to remove air bubbles, like with liquid injections, and partially depressing the plunger prior to administration may cause the implant to fall from the syringe.

Gently peel the plastic safety tab up and away from the plunger and discard it. Remove the needle cover.

NOTE: If too much force is used when removing the plastic safety tab, the plunger can be pulled off.

3. Complete the injection:

Pinch the patient’s skin using aseptic technique at the prepared injection site. With the bevel of the needle facing up, grasp the protective sleeve of the syringe with the pointer finger, middle finger, and thumb.

NOTE: If finger placement is not comfortable, adjust so you have control of the device.

Insert the needle subcutaneously at a 30- to 45-degree angle to the skin in one continuous, deliberate motion until the protective sleeve touches the skin.

NOTE: The ZOLADEX syringe cannot be used for aspiration. If the hypodermic needle penetrates a large vessel, blood will be seen instantly in the syringe chamber. If a vessel is penetrated, withdraw the needle and inject with a new syringe elsewhere. Monitor patients for signs or symptoms of abdominal hemorrhage. Use extra care when administering ZOLADEX to patients with low BMI and/or patients receiving full dose anticoagulation. Do not penetrate into muscle or peritoneum.

While continuing to pinch the patient’s abdomen, move your fingers back to the syringe finger grip and place your thumb on the plunger. Grasping the syringe below the finger grip on the protective sleeve may prevent the protective sleeve from activating.

While grasping the finger grip, depress the plunger until you cannot depress it any further. Use sufficient force to depress the plunger, as a degree of resistance can be experienced.

After fully depressing the plunger, begin withdrawing the needle, and the SafeSystem® Syringe protective sleeve will deploy to cover the syringe. The needle itself does not retract. Dispose of the syringe in an approved sharps collector.

Icon of bar graph with arrow curving upwards

Find efficacy and safety data from the pivotal trial and more

See study results
Icon of plus sign

EMPOWER+ delivers comprehensive resources and services

View support solutions
Icon of two people talking

Need more information? A sales representative is ready to help

Request a rep

GnRH=gonadotropin-releasing hormone; VAS=visual analogue scale.

  1. ZOLADEX® (goserelin implant) 3.6 mg. Prescribing Information. TerSera Therapeutics LLC.
  2. ZOLADEX® (goserelin implant) 10.8 mg. Prescribing Information. TerSera Therapeutics LLC.
  3. Moser MA. Engineering out needle stick injuries (safety devices). The Safe Angle. Summer 2004;5-7.
  4. Data on file. TerSera Therapeutics LLC.
  5. Morgan G, Cooley C. Injection systems for two luteinising hormone-releasing hormone agonists: a comparative assessment of administration times and nurses’ perceptions. Eur J Oncol Nurs. 2005;9:334-340.
  6. Montgomery BS, Borwell JP, Higgins DM. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection. Prostate Cancer Prostatic Dis. 2005;8:66-68.
  7. Administering Subcutaneous Medications. Open Resources for Nursing (Open RN); Ernstmeyer K, Christman E, eds. Nursing Skills. 2nd ed. Chippewa Valley Technical College; 2023. Accessed August 5, 2026. https://wtcs.pressbooks.pub/nursingskills

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ZOLADEX is contraindicated in patients with known hypersensitivity to GnRH, GnRH agonist, or any of the components in ZOLADEX.

ZOLADEX is contraindicated during pregnancy unless used for palliative treatment of advanced breast cancer. If used during pregnancy, the patient should be advised of the potential hazard to the fetus.

WARNINGS AND PRECAUTIONS

Women of Childbearing Potential and Pregnancy: Women of childbearing potential should avoid becoming pregnant. ZOLADEX can cause fetal harm. Pregnancy must be excluded and effective nonhormonal contraception must be used by all premenopausal women during ZOLADEX therapy and for 12 weeks following discontinuation of therapy. 

Tumor Flare Phenomenon: Transient worsening of tumor symptoms may occur in the first few weeks of therapy in patients being treated for cancer. Monitor patients at risk for complications of tumor flare including ureteral obstruction, spinal cord compression, and increased bone pain.

Hyperglycemia and Diabetes: Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose levels and manage according to current clinical practice.

Cardiovascular Diseases: Increased risk of myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH agonists in men. Patients should be monitored for cardiovascular disease and be managed according to current clinical practice.

Hypercalcemia: Hypercalcemia has been reported in some prostate and breast cancer patients with bone metastases. Monitor and manage appropriately.

Hypersensitivity: Systemic hypersensitivity, antibody formation, and acute anaphylactic reactions have been reported in patients receiving ZOLADEX.

Severe Cutaneous Adverse Reactions: ZOLADEX can cause severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). SCARs, including SJS/TEN, DRESS, and AGEP, occurred in patients receiving ZOLADEX or other GnRH agonists, including cases with visceral involvement and/or requiring skin grafts. Monitor patients for the development of SCARs. If a SCAR is suspected, interrupt ZOLADEX until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended. If a SCAR is confirmed, or for other grade 4 skin reactions, permanently discontinue ZOLADEX.

Cervical Resistance: ZOLADEX may cause an increase in cervical resistance. Therefore, caution is recommended when dilating the cervix for endometrial ablation.

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. Consider risks and benefits.

Injection Site Injury: Injection site injury and vascular injury have been reported with ZOLADEX. Extra care should be taken when administering ZOLADEX to patients with low BMI and/or to patients receiving full dose anticoagulation.

Depression: Depression may occur or worsen in women receiving GnRH agonists, including ZOLADEX. Monitor and manage appropriately. Carefully observe women for depression, especially those with a history and consider if risks outweigh the benefits.

ADVERSE REACTIONS

In men, the most common adverse reactions (>10%) include hot flashes, sexual dysfunction, decreased erections and lower urinary tract symptoms.

In women, the most common adverse reactions (>20%) include hot flashes, vaginitis, headache, emotional lability, decreased libido, sweating, depression, acne, breast atrophy, seborrhea, and peripheral edema.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1‑800‑FDA‑1088 or www.FDA.gov/medwatch. You may also contact TerSera Therapeutics at 1‑844‑334‑4035 or medicalinformation@tersera.com.

Please see Full Prescribing Information for ZOLADEX 3.6 mg and ZOLADEX 10.8 mg.

INDICATIONS

ZOLADEX (goserelin implant) is a Gonadotropin Releasing Hormone (GnRH) agonist.

ZOLADEX 3.6 mg is indicated for:

  • Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women
  • The management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy
  • Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding

ZOLADEX 3.6 mg and ZOLADEX 10.8 mg are indicated for:

  • Use in combination with flutamide for the management of locally confined carcinoma of the prostate
  • Palliative treatment of advanced carcinoma of the prostate
Important Safety Information and Indications

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ZOLADEX is contraindicated in patients with known hypersensitivity to GnRH, GnRH agonist, or any of the components in ZOLADEX.

ZOLADEX is contraindicated during pregnancy unless used for palliative treatment of advanced breast cancer. If used during pregnancy, the patient should be advised of the potential hazard to the fetus.

WARNINGS AND PRECAUTIONS

Women of Childbearing Potential and Pregnancy: Women of childbearing potential should avoid becoming pregnant. ZOLADEX can cause fetal harm. Pregnancy must be excluded and effective nonhormonal contraception must be used by all premenopausal women during ZOLADEX therapy and for 12 weeks following discontinuation of therapy. 

Tumor Flare Phenomenon: Transient worsening of tumor symptoms may occur in the first few weeks of therapy in patients being treated for cancer. Monitor patients at risk for complications of tumor flare including ureteral obstruction, spinal cord compression, and increased bone pain.

Hyperglycemia and Diabetes: Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose levels and manage according to current clinical practice.

Cardiovascular Diseases: Increased risk of myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH agonists in men. Patients should be monitored for cardiovascular disease and be managed according to current clinical practice.

Hypercalcemia: Hypercalcemia has been reported in some prostate and breast cancer patients with bone metastases. Monitor and manage appropriately.

Hypersensitivity: Systemic hypersensitivity, antibody formation, and acute anaphylactic reactions have been reported in patients receiving ZOLADEX.

Severe Cutaneous Adverse Reactions: ZOLADEX can cause severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). SCARs, including SJS/TEN, DRESS, and AGEP, occurred in patients receiving ZOLADEX or other GnRH agonists, including cases with visceral involvement and/or requiring skin grafts. Monitor patients for the development of SCARs. If a SCAR is suspected, interrupt ZOLADEX until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended. If a SCAR is confirmed, or for other grade 4 skin reactions, permanently discontinue ZOLADEX.

Cervical Resistance: ZOLADEX may cause an increase in cervical resistance. Therefore, caution is recommended when dilating the cervix for endometrial ablation.

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. Consider risks and benefits.

Injection Site Injury: Injection site injury and vascular injury have been reported with ZOLADEX. Extra care should be taken when administering ZOLADEX to patients with low BMI and/or to patients receiving full dose anticoagulation.

Depression: Depression may occur or worsen in women receiving GnRH agonists, including ZOLADEX. Monitor and manage appropriately. Carefully observe women for depression, especially those with a history and consider if risks outweigh the benefits.

ADVERSE REACTIONS

In men, the most common adverse reactions (>10%) include hot flashes, sexual dysfunction, decreased erections and lower urinary tract symptoms.

In women, the most common adverse reactions (>20%) include hot flashes, vaginitis, headache, emotional lability, decreased libido, sweating, depression, acne, breast atrophy, seborrhea, and peripheral edema.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1‑800‑FDA‑1088 or www.FDA.gov/medwatch. You may also contact TerSera Therapeutics at 1‑844‑334‑4035 or medicalinformation@tersera.com.

Please see Full Prescribing Information for ZOLADEX 3.6 mg and ZOLADEX 10.8 mg.

INDICATIONS

ZOLADEX (goserelin implant) is a Gonadotropin Releasing Hormone (GnRH) agonist.

ZOLADEX 3.6 mg is indicated for:

  • Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women
  • The management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy
  • Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding

ZOLADEX 3.6 mg and ZOLADEX 10.8 mg are indicated for:

  • Use in combination with flutamide for the management of locally confined carcinoma of the prostate
  • Palliative treatment of advanced carcinoma of the prostate